← All IPOs

Symbiotec Pharmalab Ltd IPO

SYMBIOTEC · Main board · PharmaceuticalsListed
Read filingAllotmentStock listed on 01 September
Price band
₹938 to ₹988
Issue size
₹1,757 Cr
Issue price
₹988
Lot size
15 shares
Listing return
0%

Listed ₹988

  1. Opens

    24 Aug 2026

  2. Closes

    27 Aug 2026

  3. Allotment

    28 Aug 2026

  4. Listing

    1 Sep 2026

Subscription

About the company

Symbiotec Pharmalab is a pharmaceutical and biotechnology firm that develops and manufactures active pharmaceutical ingredients (APIs), biotech products, and complex injectables. It works across three platforms: organic chemistry, biotechnology, and complex injectables. The company offers more than 60 corticosteroid and steroid hormone APIs, such as hydrocortisones, betamethasone, methylprednisolones, progesterones, estrogens, and testosterone. It also provides contract development and manufacturing organisation (CDMO) services to pharmaceutical and nutraceutical companies.

As of March 31, 2026, Symbiotec had two operational API plants in Rau and Pithampur, Madhya Pradesh. It has also commissioned a biomanufacturing facility in Ujjain and a complex injectables facility in Mhow, Madhya Pradesh. The company runs three R&D centres in Indore, each focused on organic chemistry, biotechnology, or complex injectables. Its products and services have reached over 200 customers in more than 40 countries.

Founded2002MDMr. Anil Satwani

Objective of IPO proceeds

ParticularsEstimated amount (₹ Cr.)
Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company112.5
General corporate purposes—

Key performance indicators (KPIs)

for the fiscal year ended March 31, 2026

  • ROE11.19%
  • ROCE11.56%
  • EBITDA Margin26.59%
  • PAT Margin12.6%
  • Return on Net Worth (RoNW)9.48%

Net Asset Value (NAV) per Equity Share

184.69

EPS (Pre-IPO)

19.1

View table
KPIValue (for the fiscal year ended March 31, 2026)
ROE (%)11.19
ROCE (%)11.56
EBITDA Margin (%)26.59
PAT Margin (%)12.6
Return on Net Worth (RoNW) (%)9.48
Net Asset Value (NAV) per Equity Share (₹)184.69
EPS (Pre-IPO) (₹)19.1

Financials

₹ crore

Revenue

869.15

+15.6%

Total Assets

1,780.79

+12.7%

Profit

109.9

+13.6%
View table
Line202420252026
Revenue716.25751.55869.15
Total Assets1,294.781,579.651,780.79
Profit100.0596.78109.9

Book running lead managers & registrar

Book running lead managersJM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited, Nomura Financial Advisory, Securities (India) Private Limited
Registrar to the issueMUFG Intime India Private Limited

Symbiotec Pharmalab IPO contact details

Company nameSymbiotec Pharmalab Limited
Registered office385/2, Pigdamber, Rau, Mhow, Indore – 453 331, Madhya Pradesh, India
Phone+91 731 667 6405
Emailsecretarial@symbiotec.com
Websitewww.symbiotec.com

Symbiotec Pharmalab IPO registrar contact details

Company nameMUFG Intime India Private Limited
Phone+91 810 811 4949
Emailsymbiotecpharmalab.ipo@in.mpms.mufg.com
Websitein.mpms.mufg.com/

Thesis

  • 1

    In FY26, the company held a global volume market share of 38.2% in corticosteroid APIs and 23.8% in steroidal-hormone APIs (excluding androstenedione and hydroxyprogesterone caproate), with product-specific shares of 80.1% in hydrocortisone, 76.4% in testosterone, and 76.0% in methylprednisolone.

  • 2

    Its portfolio of over 60 corticosteroid and steroidal-hormone APIs, in sterile and non-sterile forms, covered about 90% of such API products as of March 31, 2026, and included 43 drug master files with the US FDA and 23 certificates of suitability from the EDQM.

  • 3

    The company serves both domestic and international markets, with exports contributing Rs 582.64 crore, Rs 414.78 crore, and Rs 429.52 crore in FY26, FY25, and FY24, or 67.04%, 55.19%, and 59.97% of revenue from operations; as of March 31, 2026, it had over 200 customers across more than 40 countries, including more than 50 domestic and over 150 export customers.

  • 4

    Its vertically integrated, multi-scale manufacturing platform had, as of March 31, 2026, a maximum chemical synthesis capacity of 584.67 MT, fermentation capacity of 700 KL, and complex injectable capacity of 20 million vials; backward integration lets it produce key starting materials for products that account for over 80% of revenue, lowering reliance on external intermediates.

  • 5

    The Rau and Pithampur facilities hold approvals from regulators including the US FDA, EU-GMP, and WHO-GMP.

  • 6

    R&D spans organic chemistry, biotechnology, and complex injectables through three dedicated centres in Indore as of March 31, 2026; R&D spending was Rs 29.69 crore, Rs 31.14 crore, and Rs 20.51 crore in FY26, FY25, and FY24, equal to 3.42%, 4.14%, and 2.86% of revenue from operations.

  • 7

    Revenue from operations has grown from Rs 716.25 crore in FY24 to Rs 751.55 crore in FY25 and Rs 869.15 crore in FY26.

Application details

  • Regular

    ₹938 - ₹988 · Upto ₹2 Lakhs

    15shares
  • Employee

    ₹848 - ₹898 · Upto ₹5 Lakhs

    ₹90 discount

    15shares
  • High Networth Individual

    ₹938 - ₹988 · ₹2 - ₹5 Lakhs

    15sharesMin 210

Figures come from the company filing. This is not a recommendation.